Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Receivables (2016 - 2025)

Neurocrine Biosciences' Change in Receivables history spans 16 years, with the latest figure at -$38.4 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 1820.0% year-over-year to -$38.4 million; the TTM value through Dec 2025 reached $210.5 million, up 428.89%, while the annual FY2025 figure was $210.5 million, 428.89% up from the prior year.
  • Change in Receivables reached -$38.4 million in Q4 2025 per NBIX's latest filing, down from $132.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $132.3 million in Q3 2025 to a low of -$38.4 million in Q4 2025.
  • Average Change in Receivables over 5 years is $26.5 million, with a median of $19.5 million recorded in 2023.
  • Peak YoY movement for Change in Receivables: soared 10750.0% in 2021, then plummeted 1820.0% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $21.7 million in 2021, then skyrocketed by 114.29% to $46.5 million in 2022, then crashed by 53.98% to $21.4 million in 2023, then plummeted by 109.35% to -$2.0 million in 2024, then tumbled by 1820.0% to -$38.4 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Change in Receivables are -$38.4 million (Q4 2025), $132.3 million (Q3 2025), and $79.7 million (Q2 2025).